Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Pipeline Snapshot as of July 28, 2021

  • Discovery Projects
  • Phase 1
    29
  • Phase 2
    40
  • Phase 3
    23
  • Registration
    8
  • Total100
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
PF-07304814
Therapeutic Area:
Hospital (Anti-Infectives)
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
SARS-CoV-2 3CL protease inhibitor (IV anti-viral)
COVID-19 Infection Phase 1 New Molecular Entity Small Molecule
PF-07242813
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
CD1a inhibitor
Atopic Dermatitis (Biologic) Phase 1 New Molecular Entity Biologic
PF-06835375
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Chemokine Inhibitor
Lupus (Biologic) Phase 1 New Molecular Entity Biologic
PF-07054894
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CCR6 Antagonist
Inflammatory Bowel Disease Phase 1 New Molecular Entity Small Molecule
danuglipron (PF-06882961) + PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist; Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis Phase 1 New Molecular Entity Small Molecule
PF-06842874
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 4,6 Inhibitor
Pulmonary Arterial Hypertension (ORPHAN - U.S.) Phase 1 New Molecular Entity Small Molecule
PF-06946860
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Growth Differentiation Factor 15 (GDF15) Monoclonal Antibody
Cachexia (Biologic) Phase 1 New Molecular Entity Biologic
PF-07258669
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Melanocortin-4 receptor (MC4R) Antagonist
Anorexia Phase 1 New Molecular Entity Small Molecule
PF-07081532
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Glucagon-like peptide 1 receptor (GLP-1R) Agonist
Diabetes Mellitus-Type 2 and Obesity Phase 1 New Molecular Entity Small Molecule
PF-07202954
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis
Project advanced
Phase 1 New Molecular Entity Small Molecule
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
EZH2 Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-06939999
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
protein arginine methyltransferase 5 (PRMT5) Inhibitor
Solid Tumors Phase 1 New Molecular Entity Small Molecule
PF-06940434
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Integrin alpha-V/beta-8 Antagonist
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-06952229
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-07062119
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
GUCY2c CD3 Bispecific Antibody
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-07104091
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK2 Inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule